← Dashboard

Compliance Alert: NEXLIZET

Configure Methodology

Pending

This brand is pending video acquisition.

Analysis will begin once the promotional video is uploaded and indexed.

NEXLIZET | Esperion Therapeutics, Inc. | DTC Broadcast

FDA Letter Jan 27, 2026

Master

Visual

N/A

Efficacy

N/A

Fair Balance

N/A

Adeq Prov

N/A

Lifecycle

10%

Video Timeline

0s15s30s45s60s

No visual distractions detected

Recommendations

high

Escalate to regulatory affairs: FDA enforcement letter on file (Dec 19, 2025). Verify remediation status in PromoMats and confirm all content modifications address cited violations before next distribution.

FDA Enforcement Action on File

FDA Letter Dec 19, 2025 View PDF →

visual distraction

Animated Lipid Lurker characters swimming, diving, doing flips distract from risk information

false exclusivity claims

Claims to be 'only nonstatin' approved by FDA when PCSK9 inhibitors are also approved

Video not available for preview